Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Dolutegravir Sodium; Lamivudine Patent Expiration

Dolutegravir Sodium; Lamivudine is Used for the treatment of HIV infection. It was first introduced by Viiv Healthcare Co in its drug Dovato on Apr 8, 2019.


Dolutegravir Sodium; Lamivudine Patents

Given below is the list of patents protecting Dolutegravir Sodium; Lamivudine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Dovato US11234985 Antiviral therapy Jan 24, 2031 Viiv Hlthcare
Dovato US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Oct 05, 2027 Viiv Hlthcare
Dovato US8129385

(Pediatric)

 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Apr 05, 2028 Viiv Hlthcare
Dovato US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates Dec 08, 2029 Viiv Hlthcare
Dovato US9242986

(Pediatric)

 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates Jun 08, 2030 Viiv Hlthcare


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳